Austin Tenn-McClellan

Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies

Daniel Robbins, Mark Noviski, Ying Siow Tan et al. · Journal of Medicinal Chemistry · 2024 · 96 citations · Full text

Life Sciences, Oncology, Pharmacology +17

Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies

Daniel Robbins, Mark Noviski, Ryan B. Rountree et al. · Blood · 2021 · 50 citations

Medicine, Hematology, Oncology +11

Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies

Daniel Robbins, Aileen Kelly, May Tan et al. · Blood · 2020 · 46 citations

Veterinary Medicine, Molecular Biology, Oncology +13

NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts

Deyi Zhang, Hailey M. Harris, Jonathan Chen et al. · Blood · 2022 · 29 citations · Full text

Medicine, Molecular Biology, Oncology +7

Abstract 1595: Small molecule inhibition of the ubiquitin ligase CBL-B results in potent T and NK cell mediated anti-tumor response

Ryan B. Rountree, Frederick Cohen, Austin Tenn-McClellan et al. · Cancer Research · 2021 · 11 citations

Life Sciences, Cell Biology, Immunology +16